Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,